# Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

> **NCT05866679** · PHASE1 · SUSPENDED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Hyperpolarized 13-C-pyruvate

## Key facts

- **NCT ID:** NCT05866679
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-04-12
- **Primary completion:** 2026-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Suspension
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05866679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05866679, "Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05866679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*